CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 346 participants.
Also called NCT05267886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 346 participants
- Registry
-
NCT05267886
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT05267886. Randomized; triple masking; primary purpose treatment. Start 2022-03-05 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- Acronym
- DOREMI-2
- Condition
- Shock, Cardiogenic
- Intervention (Drug)
- Dobutamine
- Intervention (Drug)
- Milrinone
- Intervention (Drug)
- Normal Saline
- Lead sponsor
- Ottawa Heart Institute Research Corporation
Record details
- Record id
cardio:ct-nct05267886- Content hash
545022289f229bda15d38e89240975f6010e160d46d4d121e1466f766cbc6d21